Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213306802> ?p ?o ?g. }
- W4213306802 endingPage "596" @default.
- W4213306802 startingPage "586" @default.
- W4213306802 abstract "We analyzed the prognostic factors for treatment outcomes amongst 34 patients with adult Burkitt lymphoma (BL) who received rituximab with standard first-line chemotherapy. Seven patients had human immunodeficiency virus (HIV)-associated BL. Overall, we observed a complete remission (CR) rate of 91.2%, and 10-year progression-free survival (PFS) and overall survival (OS) was 84.8 and 88.2%, respectively. In patients with concomitant HIV, the prognosis was not different with 10-year PFS of 100% and OS of 88.2%. The majority (71.4%) of HIV-associated BL patients received dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and had excellent outcomes with 100% CR and no relapses. Central nervous system (CNS) disease, bone marrow involvement and elevated serum lactate dehydrogenase (LDH) levels more than 3 times upper limit of normal (ULN) were associated with poorer survival outcomes. Patients with refractory disease, whilst uncommon (n = 4), had dismal outcomes. Patients with adult BL, including HIV-related cases, harbor generally good prognosis in the modern era." @default.
- W4213306802 created "2022-02-24" @default.
- W4213306802 creator A5011817862 @default.
- W4213306802 creator A5018335994 @default.
- W4213306802 creator A5032292277 @default.
- W4213306802 creator A5038667383 @default.
- W4213306802 creator A5044506875 @default.
- W4213306802 creator A5046519734 @default.
- W4213306802 creator A5065920111 @default.
- W4213306802 creator A5073242341 @default.
- W4213306802 creator A5076871250 @default.
- W4213306802 creator A5077032051 @default.
- W4213306802 creator A5085639508 @default.
- W4213306802 creator A5087446798 @default.
- W4213306802 date "2022-02-19" @default.
- W4213306802 modified "2023-09-30" @default.
- W4213306802 title "Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy" @default.
- W4213306802 cites W1565609767 @default.
- W4213306802 cites W1696263873 @default.
- W4213306802 cites W1967008538 @default.
- W4213306802 cites W1969582706 @default.
- W4213306802 cites W1969803702 @default.
- W4213306802 cites W1972078736 @default.
- W4213306802 cites W1975280591 @default.
- W4213306802 cites W1987587866 @default.
- W4213306802 cites W1994482907 @default.
- W4213306802 cites W1995939575 @default.
- W4213306802 cites W2012963121 @default.
- W4213306802 cites W2016307324 @default.
- W4213306802 cites W2017109715 @default.
- W4213306802 cites W2021619016 @default.
- W4213306802 cites W2030286725 @default.
- W4213306802 cites W2047522348 @default.
- W4213306802 cites W2050529097 @default.
- W4213306802 cites W2070381192 @default.
- W4213306802 cites W2081754808 @default.
- W4213306802 cites W2103351728 @default.
- W4213306802 cites W2112539589 @default.
- W4213306802 cites W2114941023 @default.
- W4213306802 cites W2124368059 @default.
- W4213306802 cites W2178297673 @default.
- W4213306802 cites W2310716991 @default.
- W4213306802 cites W2319774285 @default.
- W4213306802 cites W2334417343 @default.
- W4213306802 cites W2613453921 @default.
- W4213306802 cites W2734666624 @default.
- W4213306802 cites W2773985729 @default.
- W4213306802 cites W2901551598 @default.
- W4213306802 cites W2971529736 @default.
- W4213306802 cites W3003465539 @default.
- W4213306802 cites W3004936895 @default.
- W4213306802 cites W3009742090 @default.
- W4213306802 cites W3031804664 @default.
- W4213306802 cites W3042270775 @default.
- W4213306802 cites W3126996612 @default.
- W4213306802 cites W4206378482 @default.
- W4213306802 cites W4293112737 @default.
- W4213306802 doi "https://doi.org/10.1080/10428194.2022.2027402" @default.
- W4213306802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35188049" @default.
- W4213306802 hasPublicationYear "2022" @default.
- W4213306802 type Work @default.
- W4213306802 citedByCount "2" @default.
- W4213306802 countsByYear W42133068022022 @default.
- W4213306802 countsByYear W42133068022023 @default.
- W4213306802 crossrefType "journal-article" @default.
- W4213306802 hasAuthorship W4213306802A5011817862 @default.
- W4213306802 hasAuthorship W4213306802A5018335994 @default.
- W4213306802 hasAuthorship W4213306802A5032292277 @default.
- W4213306802 hasAuthorship W4213306802A5038667383 @default.
- W4213306802 hasAuthorship W4213306802A5044506875 @default.
- W4213306802 hasAuthorship W4213306802A5046519734 @default.
- W4213306802 hasAuthorship W4213306802A5065920111 @default.
- W4213306802 hasAuthorship W4213306802A5073242341 @default.
- W4213306802 hasAuthorship W4213306802A5076871250 @default.
- W4213306802 hasAuthorship W4213306802A5077032051 @default.
- W4213306802 hasAuthorship W4213306802A5085639508 @default.
- W4213306802 hasAuthorship W4213306802A5087446798 @default.
- W4213306802 hasConcept C126322002 @default.
- W4213306802 hasConcept C141071460 @default.
- W4213306802 hasConcept C143998085 @default.
- W4213306802 hasConcept C2776694085 @default.
- W4213306802 hasConcept C2776755627 @default.
- W4213306802 hasConcept C2778119113 @default.
- W4213306802 hasConcept C2779338263 @default.
- W4213306802 hasConcept C2779384505 @default.
- W4213306802 hasConcept C2779429289 @default.
- W4213306802 hasConcept C2780653079 @default.
- W4213306802 hasConcept C2780790343 @default.
- W4213306802 hasConcept C71924100 @default.
- W4213306802 hasConcept C90924648 @default.
- W4213306802 hasConceptScore W4213306802C126322002 @default.
- W4213306802 hasConceptScore W4213306802C141071460 @default.
- W4213306802 hasConceptScore W4213306802C143998085 @default.
- W4213306802 hasConceptScore W4213306802C2776694085 @default.
- W4213306802 hasConceptScore W4213306802C2776755627 @default.
- W4213306802 hasConceptScore W4213306802C2778119113 @default.
- W4213306802 hasConceptScore W4213306802C2779338263 @default.
- W4213306802 hasConceptScore W4213306802C2779384505 @default.